December 23, 2020: Cassiopea SpA

Cassiopea Announces Management Change

Pierpaolo Guzzo to replace Chris Tanner as Chief Financial Officer

Cassiopea SpA, today announced that Chris Tanner is retiring as Chief Financial Officer as of December 31, 2020. Chris Tanner served as Cassiopea’s Chief Financial Officer since its formation and helped bring the Company public in 2015. At the meeting of December 22, 2020, the board approved the nomination of Pierpaolo Guzzo as Chief Financial Officer of Cassiopea starting January 1, 2021. Pierpaolo Guzzo is a Certified Public Accountant, with an extensive track record in accounting, private equity and merchant banking; he will retain his role as board member of Cassiopea.

Please read the whole article here

Cassiopea SpA

December 22, 2020: Apogenix AG

COVID-19: targeted treatment trial launched in Vienna

A phase II clinical trial of a treatment for COVID-19 patients is currently starting at the Medical University of Vienna as a sub-study of the Austrian CoronaVirus Adaptive Clinical Trial (ACOVACT). The trial was initiated as an academia-industry collaboration (investigator Initiated trial) between Apogenix AG, a biotech company based in Heidelberg, and their scientific consultant Henning Walczak and his teams at the University of Cologne and University College London (UCL).

Please read the whole article here

Apogenix AG

December 21, 2020: Heidelberg Pharma AG

Inside information pursuant to Article 17 MAR

Heidelberg Pharma AG Receives Shareholder Loan Based on an Existing Financing Commitment

Heidelberg Pharma AG today announced that it has signed a subordinated loan agreement for a total amount of EUR 15 million with its main shareholder dievini Hopp BioTech holding GmbH & Co. KG, Walldorf, Germany. The amount of the loan corresponds to the financing commitment from 21 July 2020 that will secure the company’s cash reach until mid-2021.

Please read the whole article here

Heidelberg Pharma AG

December 21, 2020: CureVac AG

CureVac and the University Medical Center Mainz Start Phase 3 Clinical Trial for COVID-19 Vaccine Candidate, CVnCoV, in Healthcare Workers

Study to assess safety and immunogenicity of CVnCoV
Study builds on observational epidemiological study

CureVac N.V., a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), announced today that the first participant in a clinical Phase 3 study with its COVID-19 vaccine, CVnCoV, in healthcare workers at the University Medical Center Mainz will be vaccinated on December 22, 2020. The study aims to evaluate the safety and immunogenicity of CVnCoV administered as a two-dose schedule of 12 µg. The trial follows an epidemiological, non-interventional study conducted with healthcare workers from the University Hospital in Mainz.

Please read the whole article here

CureVac AG

December 18, 2020: Cosmo Pharmaceuticals NV

Cosmo Pharmaceuticals Announces Senior Leadership Change

Cosmo Pharmaceuticals N.V today announced that Mr. Giuseppe Cipriano, the current COO, will retire for personal reasons on the 31st of December 2020 and will not take up the position of Chief People Officer as previously announced. Such position will be taken up, effective 15 January 2021, by Mr. Biagio Viganò.

Please read the whole article here

Cosmo Pharmaceuticals NV

December 15, 2020: AC Immune SA

AC Immune Receives Competitive Target ALS Foundation Grant to Accelerate the Development of Proprietary Phosphorylated TDP-43 Immuno-assay

Grant provides USD 600,000 in funding to support a world-class collaboration between AC Immune and Massachusetts General Hospital

Proprietary SupraAntigenTM platform continues to accelerate development of first- and best-in class antibody therapeutics and diagnostics for neurodegenerative diseases

AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced the receipt of a highly competitive grant awarded by Target ALS. The grant, which was awarded in response to the organization’s call for new industry-led biomarker consortia projects, will support a world-class collaboration between AC Immune and Investigators at the Healey Center for ALS at Massachusetts General Hospital to accelerate the development of the Company’s proprietary immuno-assays to detect disease-associated forms of TAR DNA-binding protein 43 (TDP-43) in cerebrospinal fluid and blood samples.

Please read the whole article here

AC Immune SA

December 15, 2020: Cosmo Pharmaceuticals NV

Cosmo Pharmaceuticals Announces Amendment of its Investment Agreement with Acacia

Cosmo Pharmaceuticals N.V. today announced that, on 14 December 2020, Acacia Pharma Group plc (“Acacia”) (EURONEXT: ACPH) and Cosmo entered into an amendment agreement (the “Amendment Agreement”) being an amendment to the Investment Agreement between the parties dated 10 January 2020, pursuant to which Acacia and Cosmo agreed that, in exchange for Cosmo prioritising the packaging and labelling production run for BYFAVOTM for supply in the US, Acacia shall make the EUR 5 million payment due on the first commercial sale of BYFAVOTM in advance of the first commercial sale of BYFAVOTM and by no later than 31 December 2020.

Please read the whole article here

Cosmo Pharmaceuticals NV

December 14, 2020: CureVac AG

CureVac Commences Global Pivotal Phase 2b/3 Trial for COVID-19 Vaccine Candidate, CVnCoV

First individual enrolled in Phase 2b/3 study to assess efficacy and safety of CVnCoV at 12 µg
Study expected to enroll more than 35,000 participants, focusing on Europe and Latin America

CureVac N.V., a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), announced today that it has enrolled the first participant in the pivotal Phase 2b/3 study of its mRNA vaccine candidate, CVnCoV, against COVID-19. The randomized, observer blind, placebo-controlled Phase 2b/3 trial called HERALD will assess the safety and efficacy of CVnCoV in adults at a dose of 12 µg. The study is expected to include more than 35,000 participants at sites in Europe and Latin America.

Please read the whole article here

CureVac AG

December 9, 2020: CureVac AG

CureVac and Fareva Sign Agreement For Fill & Finish Manufacturing of Curevac’s COVID-19 Vaccine Candidate, CVnCoV

CureVac N.V., a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), and Fareva today announced an agreement regarding the fill & finish manufacturing of CureVac´s COVID-19 vaccine candidate, CVnCoV, at Fareva’s Pau and Val-de-Reuil-sites in France.

Please read the whole article here

CureVac AG

December 8, 2020: CureVac AG

Moderne Wärme im Cyber Valley: Stadtwerke Tübingen versorgen neues Produktionsgebäude von CureVac

Klimafreundliche Kombination aus Fernwärme und Dampfkesseln

Im Tübinger Cyber Valley baut das biopharmazeutische Unternehmen CureVac seine neue industrielle Produktionsanlage. Die Wärme für das hochmoderne Gebäude kommt von den Stadtwerken Tübingen (swt). Es ist eines der größten Wärmeprojekte am Standort Obere Viehweide und zeigt, wie eine effiziente, sichere und klimafreundliche Energieversorgung aussehen kann.

Please read the whole article here

CureVac AG